Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • Long acting Ivabradine...

Long acting Ivabradine improves cardiac function in heart failure patients: FIRST study

dr. Abhimanyu UppalWritten by dr. Abhimanyu Uppal Published On 2022-08-03T10:00:34+05:30  |  Updated On 2022-08-03T11:58:39+05:30
Long acting Ivabradine improves cardiac function in heart failure patients: FIRST study

Although Ivabradine has been shown to improve clinical outcomes of chronic heart failure but the conventional formulation has the disadvantage of short duration of action and hence needs twice daily dosing. Evaluating the role of ivabradine hemisulfate sustained release (SR), a novel long-acting formulation that needs only once daily, investigators from FIRST study (published this week in...

Although Ivabradine has been shown to improve clinical outcomes of chronic heart failure but the conventional formulation has the disadvantage of short duration of action and hence needs twice daily dosing. Evaluating the role of ivabradine hemisulfate sustained release (SR), a novel long-acting formulation that needs only once daily, investigators from FIRST study (published this week in JACC), have shown that ivabradine SR, in addition to optimum standard therapy, improves heart function in patients with HFrEF. The new regimen thus aids to simplify the heart failure "polytherapy" regimens being currently prescribed worldwide and may potentially improve adherence.

Compliance with the guideline directed medical therapy is important in the optimal management of heart failure (HF), and medication dosing frequency has an important effect on adherence. It is estimated that only 50% or fewer chronically ill patients adhere to their prescribed medications. Thus, the current challenge is to reduce the complexity of HF treatment without losing the efficacy.

In the present study, patients with stabilized HFrEF in NYHA functional class II-IV were enrolled and randomized to receive placebo or ivabradine SR in addition to standard medications. The primary endpoint was the change of left ventricular (LV) end-systolic volume index from baseline to week 32.

Concerning the primary endpoint, at 32-week follow-up, a significant improvement in left ventricular end-systolic volume index (LVESVI) was observed in both arms with a significantly greater effect in the ivabradine SR arm.

Ivabradine SR therapy also exhibited superiority in improving left ventricular end-diastolic volume index, LVEF, resting heart rate, Kansas City Cardiomyopathy Questionnaire overall, and HF hospitalization/cardiovascular disease.

More patients in the ivabradine SR group demonstrated reductions in N-terminal pro–B-type natriuretic peptide levels of at least 30%. No difference was observed in all-cause mortality or in the 6-minute walk test. In fact, the trial showed a reduction in the complexity of ivabradine-HF treatment without loss of efficacy.

The FIRST results reinforce heart rate as the target of HF treatment, which is one step toward simplifying the management of HF with efficacy. The complexity and polyintervention in HF treatment are matters of great concern. Another class of rate limiting drugs, the β-blockers are strongly recommended across major guidelines of HFrEF but in clinical practice due to need for dose uptitration or due to multitude of side effects,the optimal heart rate is not easy to achieve with these drugs alone. A single daily dosing regimen of Ivabrdaine in such scenarios will be extremely useful.

"The development of new patient-centered strategies to reduce the complexity of HF treatment without losing the efficacy is warranted", notes Bocchi et al in an accompanying editorial.

"Ivabradine SR once daily in addition to optimum standard therapy improved ventricular remodeling, cardiac function, and living quality in patients with HFrEF. The side-effects of this drug are mild and tolerable. Our findings indicate the tremendous potential for this new formulation to become a feasible alternative in the therapeutic regimen for chronic heart failure", conclude authors Ye et al conclude.

Source: JACC:

1. J Am Coll Cardiol. 2022 Aug, 80 (6) 584–594

2. J Am Coll Cardiol. 2022 Aug, 80 (6) 595–597

heart failure drug heart failure with reduced ejection fraction 
dr. Abhimanyu Uppal
dr. Abhimanyu Uppal

    MBBS, MD , DM Cardiology

    Dr Abhimanyu Uppal completed his M. B. B. S and M. D. in internal medicine from the SMS Medical College in Jaipur. He got selected for D. M. Cardiology course in the prestigious G. B. Pant Institute, New Delhi in 2017. After completing his D. M. Degree he continues to work as Post DM senior resident in G. B. pant hospital. He is actively involved in various research activities of the department and has assisted and performed a multitude of cardiac procedures under the guidance of esteemed faculty of this Institute. He can be contacted at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X